Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction

• Published in: Journal of immunotherapy with emphasis on tumor immunology Vol. 13; no. 1; p. 49
• Main Authors: Samlowski, W E, Park, K J, Galinsky, R E, Ward, J H, Schumann, G B
• Format: Journal Article
• Language: English
• Published: United States 01-01-1993
• Subjects: Adult; Carcinoma - drug therapy; Carcinoma - secondary; Cerebrospinal Fluid - cytology; Cerebrospinal Fluid Pressure - drug effects; Female; Humans; Interleukin-2 - adverse effects; Interleukin-2 - pharmacokinetics; Interleukin-2 - therapeutic use; Interleukin-6 - cerebrospinal fluid; Intracranial Pressure - drug effects; Killer Cells, Lymphokine-Activated; Melanoma - drug therapy; Meningeal Neoplasms - drug therapy; Meningeal Neoplasms - secondary; Tumor Necrosis Factor-alpha - cerebrospinal fluid
• ISSN: 1067-5582
• DOI: 10.1097/00002371-199301000-00007

A patient with interleukin (IL)-2 responsive metastatic melanoma developed meningeal carcinomatosis. Treatment was attempted with intrathecal (i.t.) IL-2 (5 weekly doses of 3-6 x 10(6) IU) without glucocorticosteroids. Marked increases in cerebrospinal fluid (CSF) pressure occurred 5-10 h following each IL-2 dose, resulting in reversible abnormalities of neurologic function. IL-2 clearance from the CSF ranged from 21 to 85 ml/h, with an apparent first order rate constant of 0.08-0.23 hr-1. These values were consistent with clearance by bulk flow mechanisms. Clearance also correlated directly with peak CSF pressure. Progressive increases in CSF tumor necrosis factor (TNF)-alpha and IL-6 levels, but not Il-1 alpha, were also noted over successive treatment cycles. Increasing neutrophilia (peaking at 12 h postdose) and a delayed lymphocytosis and monocytosis (at 20-30 h) were observed with each successive i.t. IL-2 dose. Activated lymphocytes were not observed in the CSF, however, suggesting that an exogenous source of activated lymphokine-activated killer (LAK) cells may be helpful in obtaining effective antitumor responses.